Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal trophic factors
- Development stage
- Preclinical
- Lead developer
- Medistem Panama
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular, Intramuscular, Intranasal, Intravenous, Subcutaneous
01
Overview
Allogeneic mesenchymal trophic factors (MTF) is a cell-free therapeutic preparation developed by Medistem Panama and its subsidiary Translational Biosciences. Derived from the secretome of human umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs), specifically their proprietary "Golden Cells", this therapy consists of a complex mixture of extracellular vesicles, exosomes, growth factors, cytokines, and anti-inflammatory agents (such as PGE2, FGF, and BDNF) naturally secreted by MSCs during culture. MTF is designed to promote tissue repair, reduce inflammation, and support healing without the use of whole cells. It has been investigated for the treatment of osteoarthritis, asthma, and other inflammatory or degenerative conditions, and is administered via various routes including intra-articular, subcutaneous, intramuscular, and intranasal.
- Other names
- Allogeneic MSC-derived trophic factorsMesenchymal Trophic FactorsMTF
02
Targets
FGFR (FGFR family)NTRK2 (Tropomyosin-related kinase receptor type B)PTGER (Prostaglandin E2 receptor)
Beyond the preview
Go deeper on allogeneic mesenchymal trophic factors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal trophic factors.